Share
Request for Information: Arbor Research is soliciting information from qualified companies to participate in the PAn-european Registry Addressing Difelikefalin In Goal-oriented Medical treatment for dialysis-related pruritus (PARADIGM) study as the regulatory partner for Ethics Committee submission and coordination in the United Kingdom.
Review details here: PARADIGM RFI UK
Arbor Research, LLC is pleased to announce the award of three domains on the GSA OASIS+ Total Small Business vehicle. Arbor Research is poised to offer solutions in the following areas: Management and Advisory Services: Providing agencies with specialized management and consulting services that improve efficiency, performance, and delivery of results. Technical and Engineering Solutions:
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal
The Dialysis Outcomes and Practice Patterns Study (DOPPS) Program at Arbor Research Collaborative for Health is pleased to share their recent publication recognized as one of the most- downloaded articles at Kidney International Reports in the past few weeks titled “Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the